Aurora Cannabis Q4/FY2026 results meet expectations; shifts focus to European medical cannabis amid Canadian market challenges.

Aurora Cannabis reported Q4 and full-year 2026 results largely in line with management's expectations. The company is strategically exiting lower-margin consumer cannabis and plant propagation to concentrate on the expanding European medical cannabis market. However, regulatory changes in Canada are expected to negatively impact sales and margins in fiscal year 2027. Despite this, the stock remains undervalued at about 2 times estimated FY2027 EV/adjusted EBITDA. The analyst lowered the price target from $6.30 to $4.80 but maintained a buy rating, highlighting the company's potential in the medical cannabis sector.